SLC22A12 and type 2 diabetes mellitus: Almost 60% of our patients had type 2 diabetes, and over 70% of patients have CKD; therefore, present study could observe the effect of a novel selective URAT1 inhibitor, dotinurad on metabolic and renal parameters in CKD and DKD patients.